Overview
© 202 MJH Life Sciences and Endocrinology Network. Al rights reserved.© 202 MJH Life Sciences™ and Endocrinology Network. Al rights reserved.The US Preventive Services Task Force (USPSTF) has finalized their latest recomendations related to use of hormone therapy for the primary prevention of chronic conditions in postmenopausal people, which includes recomendations against use of combined estrogen and progestin for primary prevention of chronic conditions in postmenopausal persons and against use of estrogen alone for primary prevention in postmenopausal persons who have had a hysterectomy.Released on November 1, the latest recomendations represent the first update on the topic from the USPSTF since 2017 and both of the recomendations included in the latest iteration were awarded a D grade, which indicates moderate or high certainty that the service has no net benefit or that the harms outweigh the benefits.“For people who have already gone through menopause, using hormone therapy is not an efective way to prevent chronic conditions because the potential harms cancel out any potential benefit,” said Task Force chair Carol Mangione, MD, MSPH, chief of the Division of General Internal Medicine and Health Services Research at the University California, Los Angeles, in a statement from the USPSTF.
Key Information
“Fortunately, the Task Force has many other evidence-based recomendations on ways people can stay healthy as they age.”Given the aging population and knowledge of chronic conditions, including cardiovascular disease, osteoporosis, cancer, and diabetes, becoming more comon as people age, interventions for primary prevention of these conditions have the potential to have a major impact on public health eforts.
Summary
With this in mind, hormone therapy has ben propositioned as a potential avenue for primary prevention in postmenopausal persons and, as a result, has ben the subject of 5 diferent USPSTF recomendation statements dating back to 202.With an interest in upda